Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virios Therapeutics Inc (NQ: VIRI )

0.4250 +0.0038 (+0.90%)
Streaming Delayed Price Updated: 1:44 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virios Therapeutics Inc

< Previous 1 2 Next >
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia 
Via MarketBeat
Exposures Product Safety
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics, Inc. Announces Closing of Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics, Inc. Announces Pricing of Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics, Inc. Announces Proposed Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Via ACN Newswire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce... 
From RedChip
Via AccessWire
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces New Social Media Profiles
From Virios Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.